Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itraconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP8B1 | Q9UNU6 | 2/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | CCR4 | P51679 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itraconazole SCHEMBL13575828 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL18241655 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL23934 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL14875797 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL12392762 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL14875571 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL18073408 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL14875749 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL18073409 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL23935 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4319556-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | Gulba, Dietrich (DE) | 2024-02-14 | — | — | EP | claimed |
| WO-2022214485-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | BIOROXX GMBH (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-4743111-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | Rutgers, the State University of New Jersey (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| JP-2026005802-A | — | 株式会社バイオジェノミクス | 2026-01-16 | — | — | JP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-3346998-B1 | TOPICAL FILM DELIVERY SYSTEM | SIDMAK LABORATORIES INDIA PVT LTD (IN) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025015118-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-01-16 | — | — | WO | disclosed |
| JP-7584834-B1 | — | 株式会社バイオジェノミクス | 2024-11-18 | — | — | JP | disclosed |
| US-12115213-B2 | Methods of treating fungal infections | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-15 | — | — | US | disclosed |
| US-12023343-B2 | Thermo-kinetic mixing for pharmaceutical applications | AustinPx, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | JOHNS HOPKINS UNIVERSITY | 2013-04-25 | — | — | US | disclosed |
| EP-2431477-A1 | POLYKETIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059038-A1 | POLYKETIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059038-A1 | POLYKETIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110262517-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262517-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059038-A1 | POLYKETIDE COMPOUND | IL5, IL15, KAT5 | CYP3A4 3180/4885ABCG2 3668/4885LMNA 2712/4885 |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | CYP3A4 563/4885ABCG2 1599/4885LMNA 1358/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | CYP3A4 563/4885ABCG2 1599/4885LMNA 1358/4885 |
| US-20110262517-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS | CYP51A1, LSS, ERG28 | CYP3A4 105/4885ABCG2 1135/4885LMNA 3464/4885 |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | TEK, KDR, FLT1 | CYP3A4 567/4885ABCG2 163/4885LMNA 4600/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP3A4 171/4885ABCG2 222/4885LMNA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.